Sonelokimab
M1095-HV-102
Phase 1 small_molecule completed
Quick answer
Sonelokimab for Relative Bioequivalence is a Phase 1 program (small_molecule) at MoonLake Immunotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- MoonLake Immunotherapeutics
- Indication
- Relative Bioequivalence
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed